Yale Startups in Formation – Rare Diseases: Inside the Veil of Business Development Evaluations

Overview: With investment levels in rare & ultra-rare diseases increasing, are they all attractive for biotechs & venture capital? What factors are executives & investors looking for in new opportunities? Please join a panel of industry veterans for discussion and Q&A “Inside the Veil” of rare disease business development evaluations.

Moderator:

Dr. Akansha Bhargava, Blavatnik Fellow

Panelists:

1. Richard Brodsky, Founder & Strategy Lead, Naveos Biopharma Consulting, Yale Entrepreneur-in-Residence

2. Behrad Derakhshan, PhD, Chief Business Officer at Edgewise Therapeutics

3. Jeremy P. Springhorn, PhD, Chief Business Officer, Syros Pharmaceuticals, Inc.